Pharma IQ Members

Regulatory Legal OLD

Ensure compliance with external submission standards. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in pharmaceutical regulatory affairs to exchange ideas on best practice and share case studies on innovation within the area.

Contributor: Pharma IQ
Posted: 19/07/2016
Pharma IQ
As the serialisation industry prepares for various approaching deadlines all over the globe, Pharma IQ has created a printable map to assist with your worldwide track and trace compliance strategies. Full Content »
Contributor: Chanice Henry
Posted: 05/05/2016
Chan
When examining the known future for GMP compliance, there are a range of changes that the industry needs to brace for, including a new EU delegated act focused on investigational medicinal products. Here Pharma IQ outlines the GMP updates the market will soon be facing. Full Content »
Contributor: Chanice Henry
Posted: 28/04/2016
Chan
With a view to contribute to the industry’s ongoing progression, Pharma IQ collates the lessons learnt by hospitals during the implementation of UDIs for medical devices and how the conduct of manufacturers and hospitals could be altered to not just optimize this project’s roll out but to avoid incurring any detriment. Full Content »
Contributor: Chanice Henry
Posted: 28/04/2016
Chan
While the US advances with its coverage of medical device classes within the U.S. Food and Drug Administration (FDA) Unique Device Identification regime, other countries around the globe are progressing their own track and trace strategies for medical devices. Through the collaboration of the world’s regulatory agencies it is hoped that a synchronized approach to medical device identification will be achieved on an international level, amidst their efforts to tackle counterfeiting, increase accountability and enable safety corrective measures. (2) Full Content »
Posted: 12/04/2016
adetns
The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Full Content »
Contributor: Pharma IQ
Posted: 19/07/2016
Pharma IQ
As the serialisation industry prepares for various approaching deadlines all over the globe, Pharma IQ has created a printable map to assist with your worldwide track and trace compliance strategies. Full Content »
Contributor: Chanice Henry
Posted: 05/05/2016
Chan
When examining the known future for GMP compliance, there are a range of changes that the industry needs to brace for, including a new EU delegated act focused on investigational medicinal products. Here Pharma IQ outlines the GMP updates the market will soon be facing. Full Content »
Contributor: Chanice Henry
Posted: 28/04/2016
Chan
With a view to contribute to the industry’s ongoing progression, Pharma IQ collates the lessons learnt by hospitals during the implementation of UDIs for medical devices and how the conduct of manufacturers and hospitals could be altered to not just optimize this project’s roll out but to avoid incurring any detriment. Full Content »
Contributor: Chanice Henry
Posted: 28/04/2016
Chan
While the US advances with its coverage of medical device classes within the U.S. Food and Drug Administration (FDA) Unique Device Identification regime, other countries around the globe are progressing their own track and trace strategies for medical devices. Through the collaboration of the world’s regulatory agencies it is hoped that a synchronized approach to medical device identification will be achieved on an international level, amidst their efforts to tackle counterfeiting, increase accountability and enable safety corrective measures. (2) Full Content »
Posted: 12/04/2016
adetns
The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Full Content »
Contributor: Pharma IQ
Posted: 19/07/2016
Pharma IQ
As the serialisation industry prepares for various approaching deadlines all over the globe, Pharma IQ has created a printable map to assist with your worldwide track and trace compliance strategies. Full Content »
Contributor: Chanice Henry
Posted: 05/05/2016
Chan
When examining the known future for GMP compliance, there are a range of changes that the industry needs to brace for, including a new EU delegated act focused on investigational medicinal products. Here Pharma IQ outlines the GMP updates the market will soon be facing. Full Content »
Contributor: Chanice Henry
Posted: 28/04/2016
Chan
With a view to contribute to the industry’s ongoing progression, Pharma IQ collates the lessons learnt by hospitals during the implementation of UDIs for medical devices and how the conduct of manufacturers and hospitals could be altered to not just optimize this project’s roll out but to avoid incurring any detriment. Full Content »
Contributor: Chanice Henry
Posted: 28/04/2016
Chan
While the US advances with its coverage of medical device classes within the U.S. Food and Drug Administration (FDA) Unique Device Identification regime, other countries around the globe are progressing their own track and trace strategies for medical devices. Through the collaboration of the world’s regulatory agencies it is hoped that a synchronized approach to medical device identification will be achieved on an international level, amidst their efforts to tackle counterfeiting, increase accountability and enable safety corrective measures. (2) Full Content »
Posted: 12/04/2016
adetns
The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Full Content »